CD38 and plasma cell myeloma: Daratumumab triggers CD38+ multiple myeloma cells [via antibody-dependent cellular cytotoxicity (ADCC), complement dependent cytotoxicity (CDC), and tumor-associated macrophages (TAMs)] in sensitive and drug-resistant patients, regulates the enzyme activity of CD38, reduces the level of adenosine and reduces adenosine-induced immunosuppression.